BOCA RATON, Fla., August 28, 2025--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology clinical trial matching, today announced the launch of its new key feature on the Patient Connect app.
Neuro-symbolic, multi-agent AI system achieves 4x faster trial matching with oncologist-confirmed accuracy across 17,000+ matches, published in ESMO Real World Data and Digital Oncology special issue ...
The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, ...
SAN DIEGO--(BUSINESS WIRE)--Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a ...
Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials. The consortium, founded in 2022, is focused on ...
Massive Bio has partnered with OpenAI to automate and scale patient pre-screening for oncology and haematology clinical trials worldwide. The collaboration uses AI to convert complex eligibility ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
(MENAFN- EIN Presswire) EINPresswire/ -- Massive Bio Publishes Peer-Reviewed Prospective Study Demonstrating AI Clinical Trial Matching Four Times Faster Than Conventional Methods Study in ESMO Real ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results